Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In the third quarter of 2023, the company’s revenue surged to $63.7

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

JULY 5, 2021

The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added. ” The deal is subject to the usual conditions, including receipt of various approvals from regulators around the world.

Clinical Trials 62

Clinical Trials Clinical Trials Regulation Trials 62

The Pharma Data

DECEMBER 16, 2020

the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. and will leverage a major COVID-19 vaccine partnership the company struck with the U.K. The study will be conducted in the U.K.

Vaccination 52

Vaccination Vaccine DNA Antibody 52

pharmaphorum

DECEMBER 21, 2020

Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. He told pharmaphorum: “They are very good doctors, scientists and entrepreneurs.

Vaccination 91

Vaccination Vaccine Doctors Doctor 91

pharmaphorum

SEPTEMBER 8, 2022

However, there is a difference between the two: the toxic payloads of ADCs need to be absorbed into cancer cells, whereas radiopharmaceuticals can still do damage even when only bound to the cancer, and are particularly sensitive to radiation-induced DNA damage. Investment is flowing.

Manufacturing 102

Manufacturing Development Drugs Antibody 102

Drug Discovery World

OCTOBER 7, 2022

TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out. companies to supplement their own R&D; most novel ideas stem from academia. Tony Hickson.

HR 52

HR Research Drugs Development 52